Company / Return on Assets (ROA)
Lineage Cell Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-56.4%
FY2025
5-year range
-56.4% / -11.8%
FY2021-FY2025
Trend
-243.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) changed -243% YoY in FY2025, a notable deviation from the 9-year average annual change of -42%.
Based on SEC 10-K filings.
-56.4% in FY2025 with a 5-year CAGR of -45.6%.
Declined from -21.3% to -56.4% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -21.6pp
- 5-Year Change
- -45.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 243.2% year-over-year.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -56.4% | -243.2% |
| FY2024 | -16.4% | +22.7% |
| FY2023 | -21.3% | +38.9% |
| FY2022 | -34.8% | -194.1% |
| FY2021 | -11.8% | -9.0% |
| FY2020 | -10.8% | +70.4% |
| FY2019 | -36.6% | -86.5% |
| FY2018 | -19.7% | +27.5% |
| FY2017 | -27.1% | -6.2% |
| FY2016 | -25.5% | +44.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026